U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06982963) titled 'RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FB102 IN ADULT WITH CELIAC DISEASE' on May 13.
Brief Summary: This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Celiac Disease
Intervention:
BIOLOGICAL: FB102
FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a...